Forging new chemistry solutions
for novel antibiotics
At Forge Therapeutics, we are developing novel antibiotics targeting bacterial metalloenzymes.
As bacteria become more and more resistant to conventional antibiotics, common medical procedures such as surgery, chemotherapy, and dialysis become increasingly risky.
Over 700,000 people
worldwide die from antibiotic-resistant infections and estimates indicate that the annual toll could rise to 10 million people by 2050.
More than 2.8 Million
antibiotic-resistant infections occur in the U.S. each year, leading to more than 35,000 deaths.
Every 11 Seconds
someone in U.S. gets an antibiotic-resistant infection and every 15 minutes someone dies.
$20 Billion is estimated
to cost the U.S. each year in antibiotic resistance.
LATEST NEWS & ARTICLES
Improving data sharing to increase the efficiency of antibiotic R&D
Greater investment is needed in antibiotic R&D, and more must be done to maximize the impact of such investments. More ...
Forge Enters Into Collaboration with Roche to Develop Novel Antibiotic to Treat Lung Infections
Forge is eligible to receive $190.5M in total payments SAN DIEGO, California, March 25, 2020 – Forge Therapeutics, Inc. (Forge) ...
Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections
-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform- San Diego, California, Aug 14, 2019 – Forge Therapeutics, ...
